We are analyzing https://link.springer.com/article/10.1007/s10147-012-0417-5.

Title:
Development of treatment strategies for advanced neuroblastoma | International Journal of Clinical Oncology
Description:
Neuroblastoma is the most common cancer in childhood. The majority of patients with neuroblastoma are assigned to the high-risk group based on age at diagnosis, stage, histology, MYCN status, and DNA ploidy. Their prognosis remains unsatisfactory; the 5-year event-free survival (EFS) rate is generally 40 %. During the past 20 years, much effort has been made to reinforce chemotherapy, including the introduction of high-dose chemotherapy with autologous stem cell rescue, resulting in a 5-year EFS rate of around 30 %. Subsequently, maintenance therapy aimed at eradicating residual tumors after induction and consolidation therapies was introduced, consisting of differentiation-inducing agents, retinoids, and immunotherapy using anti-GD2 antibodies combined with cytokines. However, such additional treatment provided benefit to only 10–20 % of patients, while the prognosis of about half the patients remains poor. Currently, novel targeted agents are under development. Among them, anaplastic lymphoma kinase (ALK) inhibitors and aurora kinase A inhibitors are promising. ALK somatic mutation or gene amplification predisposing neuroblastoma development occurs in up to 15 % of neuroblastomas. Crizotinib is a dual-specific inhibitor of ALK/Met and inhibits proliferation of neuroblastoma cells harboring R1275Q-mutated ALK or amplified wild-type ALK, but not cells harboring F1174L. Instead, cells with F1174L are sensitive to another small molecule ALK inhibitor, TAE684. Aurora kinase A plays a pivotal role in centrosome maturation and spindle formation during mitosis. MLN8237 (alisertib) is a small molecule inhibitor of aurora kinase A that is currently in early-phase clinical testing. Future treatment will be individually planned, adapting targeted agents based on personal biological tumor characteristics.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

google, scholar, pubmed, article, neuroblastoma, cas, cancer, oncol, clin, group, kinase, testing, study, phase, blood, alk, oncology, children, pediatric, pediatr, childrens, cell, lymphoma, treatment, highrisk, therapy, inhibitor, antibody, patients, chemotherapy, trial, refractory, preclinical, program, monoclonal, initial, stage, anaplastic, cells, oncogene, autologous, induction, antigd, access, matthay, report, privacy, cookies, content, journal,

Topics {✒️}

granulocyte–macrophage colony-stimulating factor chimeric human/murine anti-ganglioside chimeric anti-gd2-antibody ch14 phosphatidylinositol 3-kinase-akt pathway autologous stem-cell transplantation large-cell anaplastic lymphoma chimeric anti-gd2 antibody month download article/chapter nucleophosmin-anaplastic lymphoma kinase anti-gd2 antibodies combined hematopoietic stem-cell transplantation utilizes phospholipase c-gamma high-risk group based high-risk neuroblastoma treated amplified wild-type alk long-term neurologic outcome sensitizes mycn-amplified neuroblastoma maintenance therapy aimed neuroblastoma tumor-initiating cells median progression-free survival stem cell rescue stem-cell rescue hr-nbl1/siopen trial article international journal 5-year event-free survival high-dose chemotherapy small molecule inhibitor intensive induction therapy early-phase clinical testing anaplastic lymphoma kinase targeted agents full article pdf anti-gd2 antibody standard induction chemotherapy intensive induction chemotherapy london wb high-risk neuroblastoma oral capsular 4-hydroxyphenylretinamide monoclonal antibody 3f8 privacy choices/manage cookies nucleolar protein nucleophosmin high-dose rapid human neuroblastoma cells leukocyte tyrosine kinase consolidation therapies differential inhibitor sensitivity antibody-dependent cytotoxicity cells harboring f1174l disialoganglioside directed immunotherapy stat3 induces apoptosis

Questions {❓}

Carlsen NL (1990) How frequent is spontaneous remission of neuroblastomas?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Development of treatment strategies for advanced neuroblastoma
         description:Neuroblastoma is the most common cancer in childhood. The majority of patients with neuroblastoma are assigned to the high-risk group based on age at diagnosis, stage, histology, MYCN status, and DNA ploidy. Their prognosis remains unsatisfactory; the 5-year event-free survival (EFS) rate is generally 40 %. During the past 20 years, much effort has been made to reinforce chemotherapy, including the introduction of high-dose chemotherapy with autologous stem cell rescue, resulting in a 5-year EFS rate of around 30 %. Subsequently, maintenance therapy aimed at eradicating residual tumors after induction and consolidation therapies was introduced, consisting of differentiation-inducing agents, retinoids, and immunotherapy using anti-GD2 antibodies combined with cytokines. However, such additional treatment provided benefit to only 10–20 % of patients, while the prognosis of about half the patients remains poor. Currently, novel targeted agents are under development. Among them, anaplastic lymphoma kinase (ALK) inhibitors and aurora kinase A inhibitors are promising. ALK somatic mutation or gene amplification predisposing neuroblastoma development occurs in up to 15 % of neuroblastomas. Crizotinib is a dual-specific inhibitor of ALK/Met and inhibits proliferation of neuroblastoma cells harboring R1275Q-mutated ALK or amplified wild-type ALK, but not cells harboring F1174L. Instead, cells with F1174L are sensitive to another small molecule ALK inhibitor, TAE684. Aurora kinase A plays a pivotal role in centrosome maturation and spindle formation during mitosis. MLN8237 (alisertib) is a small molecule inhibitor of aurora kinase A that is currently in early-phase clinical testing. Future treatment will be individually planned, adapting targeted agents based on personal biological tumor characteristics.
         datePublished:2012-05-16T00:00:00Z
         dateModified:2012-05-16T00:00:00Z
         pageStart:196
         pageEnd:203
         sameAs:https://doi.org/10.1007/s10147-012-0417-5
         keywords:
            Neuroblastoma
            High-risk
            Treatment
            Review
            Oncology
            Surgical Oncology
            Cancer Research
         image:
         isPartOf:
            name:International Journal of Clinical Oncology
            issn:
               1437-7772
               1341-9625
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Japan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Junichi Hara
               affiliation:
                     name:Osaka City General Hospital
                     address:
                        name:Department of Pediatric Hematology/Oncology, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Development of treatment strategies for advanced neuroblastoma
      description:Neuroblastoma is the most common cancer in childhood. The majority of patients with neuroblastoma are assigned to the high-risk group based on age at diagnosis, stage, histology, MYCN status, and DNA ploidy. Their prognosis remains unsatisfactory; the 5-year event-free survival (EFS) rate is generally 40 %. During the past 20 years, much effort has been made to reinforce chemotherapy, including the introduction of high-dose chemotherapy with autologous stem cell rescue, resulting in a 5-year EFS rate of around 30 %. Subsequently, maintenance therapy aimed at eradicating residual tumors after induction and consolidation therapies was introduced, consisting of differentiation-inducing agents, retinoids, and immunotherapy using anti-GD2 antibodies combined with cytokines. However, such additional treatment provided benefit to only 10–20 % of patients, while the prognosis of about half the patients remains poor. Currently, novel targeted agents are under development. Among them, anaplastic lymphoma kinase (ALK) inhibitors and aurora kinase A inhibitors are promising. ALK somatic mutation or gene amplification predisposing neuroblastoma development occurs in up to 15 % of neuroblastomas. Crizotinib is a dual-specific inhibitor of ALK/Met and inhibits proliferation of neuroblastoma cells harboring R1275Q-mutated ALK or amplified wild-type ALK, but not cells harboring F1174L. Instead, cells with F1174L are sensitive to another small molecule ALK inhibitor, TAE684. Aurora kinase A plays a pivotal role in centrosome maturation and spindle formation during mitosis. MLN8237 (alisertib) is a small molecule inhibitor of aurora kinase A that is currently in early-phase clinical testing. Future treatment will be individually planned, adapting targeted agents based on personal biological tumor characteristics.
      datePublished:2012-05-16T00:00:00Z
      dateModified:2012-05-16T00:00:00Z
      pageStart:196
      pageEnd:203
      sameAs:https://doi.org/10.1007/s10147-012-0417-5
      keywords:
         Neuroblastoma
         High-risk
         Treatment
         Review
         Oncology
         Surgical Oncology
         Cancer Research
      image:
      isPartOf:
         name:International Journal of Clinical Oncology
         issn:
            1437-7772
            1341-9625
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Japan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Junichi Hara
            affiliation:
                  name:Osaka City General Hospital
                  address:
                     name:Department of Pediatric Hematology/Oncology, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Clinical Oncology
      issn:
         1437-7772
         1341-9625
      volumeNumber:17
Organization:
      name:Springer Japan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Osaka City General Hospital
      address:
         name:Department of Pediatric Hematology/Oncology, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Junichi Hara
      affiliation:
            name:Osaka City General Hospital
            address:
               name:Department of Pediatric Hematology/Oncology, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pediatric Hematology/Oncology, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(214)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.54s.

LINK . SPRINGER . COM {}